RESUMO
Aflatoxin contamination is one of the most important factors jeopardizing the quality of traditional Chinese health food (TCHF) during storage. Based on our previous work, we investigated the stability of chitosan (CH) films containing turmeric essential oil (TEO) and employed CH-TEO films as inner pouches, then stored them with inoculated Coix seed, nutmeg, and Ziziphi Spinosae Semen (ZSS). We found that the stability of CH-TEO was most affected by high temperature, and these pouches dramatically decreased aflatoxin accumulation and maintained levels of marker components of each TCHF. We found that glycerol tristearat in Coix seed and jujuboside A and spinosin in ZSS were negatively correlated with aflatoxin accumulation. After three months of storage with a CH-TEO pouch, we found little change in marker components contents, but observed that Coix seed had the relative lower sensory characteristics score. In addition, acute and 90-day subchronic toxicity test in Coix seed stored with the largest amount of TEO showed no significant signs of toxicity or treatment-related changes in animals. The present study is the first report on the study of a green, efficient, and low toxicity solution for aflatoxic contamination in TCHF, and provides strong support for its future use.
Assuntos
Aflatoxinas/análise , Quitosana/química , Curcuma/química , Óleos Voláteis/química , Ziziphus/química , Animais , Coix/química , Feminino , Contaminação de Alimentos , Armazenamento de Alimentos , Temperatura Alta , Masculino , Camundongos , Myristica/química , Óleos de Plantas/química , Ratos , Testes de Toxicidade Aguda , Testes de Toxicidade Subcrônica , Triglicerídeos/químicaRESUMO
Here, we studied the preparation, characterization, anti-aflatoxigenic activity, and molecular mechanism in vitro of chitosan packaging films containing turmeric essential oil (TEO). First, we took the mechanical properties as the evaluation Index, screened for the optimum preparation conditions of packaging films with 1.5⯵L/cm2 TEO using single factor and orthogonal experiments, and characterized the film properties. We found that the addition of TEO affected the microcosmic structure of films and advanced water resistance capacity. In addition, we investigated the inhibitory effects of pure chitosan films and packaging films containing 1.5⯵L/cm2 or 3.0⯵L/cm2 TEO on the growth and conidial formation of Aspergillus flavus (A. flavus, CGMCC 3.4410), as well as the accumulation of aflatoxin over the course of seven days. We found that the packaging films possessed a prominent antifungal activity on A. flavus. Finally, we discuss preliminary results surrounding gene expression of packaging films which inhibit aflatoxin biosynthesis. The expressions levels of 16 genes related to aflatoxin biosynthesis were found to be either completely or almost completely inhibited. Therefore, the addition of the natural antifungal agent TEO in chitosan packaging films represent a remarkable method to significantly promote the development and application of antifungal packaging materials.
Assuntos
Aflatoxinas/antagonistas & inibidores , Antifúngicos/química , Antifúngicos/farmacologia , Quitosana/química , Curcuma/química , Óleos Voláteis/química , Aflatoxinas/biossíntese , Aspergillus flavus/efeitos dos fármacos , Aspergillus flavus/genética , Aspergillus flavus/metabolismo , Materiais Biocompatíveis/química , Materiais Biocompatíveis/farmacologia , Fenômenos Químicos , Embalagem de Alimentos , Regulação Fúngica da Expressão Gênica/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Modelos Biológicos , Peso Molecular , Óleos Voláteis/isolamento & purificação , Permeabilidade , Extratos Vegetais/química , Solubilidade , Análise Espectral , Vapor , TemperaturaRESUMO
BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is a favorable bariatric procedure. This study evaluated the status of LSG in China. METHODS: During the 4th International Forum of Bariatric and Metabolic Surgery in May 2016, Nanjing China, an on-the-spot questionnaire was filled out by 105 attending surgeons with experience of LSG. The feedback data was collected and analyzed. RESULTS: For preoperative preparations, surgeons preferred blood glucose control with insulin (61.0%), bowel cleaning (33.3%), and fasting and water deprivation (75.2%). For surgical techniques, surgeons preferred 36/38F bougie (86.7%), greater curvature mobilization with ultrasonic energy device (89.5%), direct transection of short gastric vessels (80%), antrum resection within 2-6 cm to the pylorus (84.8%) with 4.8 mm height stapler (72.4%), and 3.5 mm for corpus (94.3%). Whole stapler-line reinforcement, gastric sleeve fixation, leaking test, and abdominal drainage were preferred by 48.6, 62.9, 39, and 47.6% surgeons. For postoperative managements, surgeons preferred nasogastric tube insertion (33.3%), early liquid diet (69.6%), 4 weeks of liquid diet (55.2%), 2000 ml daily water intake before discharge (79%), 4 weeks of PPI (69.5%), and multi-vitamin supplementation 1 week after operation (77.1%). For postoperative complications, preferences were tachycardia as the onset of leak (81.0%) and oral contrast radiography for leak diagnosis (72.4%). Leak managements include US-guided percutaneous drainage (68.6%), nasogastric tube (87.6%), and parenteral nutrition (61%). For prolonged leak, enteral nutrition (87.6%) and Roux-en-Y bypass (84.8%) as the salvage procedure were preferred. 95.2% preferred endoscopic dilation for stricture. CONCLUSIONS: LSG is gaining its wide application in China, but standardization of LSG is urgently needed.
Assuntos
Gastrectomia/estatística & dados numéricos , Laparoscopia/estatística & dados numéricos , Obesidade Mórbida/epidemiologia , Padrões de Prática Médica/estatística & dados numéricos , China/epidemiologia , Gastrectomia/métodos , Derivação Gástrica/métodos , Derivação Gástrica/estatística & dados numéricos , Humanos , Laparoscopia/métodos , Masculino , Obesidade Mórbida/cirurgia , Duração da Cirurgia , Complicações Pós-Operatórias/epidemiologia , Período Pós-Operatório , Cirurgiões/estatística & dados numéricos , Inquéritos e QuestionáriosRESUMO
Bariatric and metabolic surgery has become the clinical hot topic of the treatment of metabolic syndromes including obesity and diabetes mellitus, but how to choose the appropriate surgical procedure remains the difficult problem in clinical practice. Clinical guidelines of American Society for Metabolic and Bariatric Surgery(ASMBS)(version 2013) introduced the procedures of bariatric and metabolic surgery mainly including biliopancreatic diversion with duodenal switch(BPD-DS), laparoscopic adjustable gastric banding (LAGB), laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy(LSG). To choose the appropriate bariatric and metabolic procedure, the surgeons should firstly understand the indications and the contraindications of each procedure. Procedure choice should also consider personal condition (body mass index, comorbidities and severity of diabetes), family and socioeconomic status (postoperative follow-up attendance, understanding of potential surgical risk of gastrectomy and patient's will), family and disease history (patients with high risk of gastric cancer should avoid LRYGB; patients with gastroesophageal reflux disease should avoid LSG) and associated personal factors of surgeons. With the practice of bariatric and metabolic surgery, the defects, especially long-term complications, of different procedures were found. For example, LRYGB resulted in higher incidence of postoperative anemia and marginal ulcer, high risk of gastric cancer as well as the requirement of vitamin supplementation and regular follow-up. Though LSG has lower surgical risk, its efficacy of diabetes mellitus remission and long-term weight loss are inferior to the LRYGB. These results pose challenges to the surgeons to balance the benefits and risks of the bariatric procedures. A lot of factors can affect the choice of bariatric and metabolic procedure. Surgeons should choose the procedure according to patient's condition with the consideration of the choice of patients. The bariatric and metabolic surgery not only manages the diabetes mellitus and weight loss, but also results in the reconstruction of gastrointestinal tract and side effect. Postoperative surgical complications and nutritional deficiency should also be considered. Thereby, individualized bariatric procedure with the full consideration of each related factors is the ultimate objective of bariatric and metabolic surgery.
Assuntos
Cirurgia Bariátrica/efeitos adversos , Cirurgia Bariátrica/métodos , Cirurgia Bariátrica/estatística & dados numéricos , Desvio Biliopancreático/efeitos adversos , Desvio Biliopancreático/métodos , Desvio Biliopancreático/estatística & dados numéricos , Diabetes Mellitus/cirurgia , Gerenciamento Clínico , Gastrectomia/efeitos adversos , Gastrectomia/métodos , Gastrectomia/estatística & dados numéricos , Derivação Gástrica/efeitos adversos , Derivação Gástrica/métodos , Derivação Gástrica/estatística & dados numéricos , Gastroplastia/mortalidade , Gastroplastia/métodos , Gastroplastia/estatística & dados numéricos , Laparoscopia/métodos , Laparoscopia/estatística & dados numéricos , Obesidade/cirurgia , Planejamento de Assistência ao Paciente , Medição de Risco/métodos , Resultado do Tratamento , Anemia/epidemiologia , Índice de Massa Corporal , Comorbidade , Contraindicações , Refluxo Gastroesofágico , Humanos , Consentimento Livre e Esclarecido , Laparoscopia/efeitos adversos , Efeitos Adversos de Longa Duração/epidemiologia , Desnutrição/epidemiologia , Gravidade do Paciente , Cooperação do Paciente , Síndromes Pós-Gastrectomia/epidemiologia , Complicações Pós-Operatórias/epidemiologia , Fatores de Risco , Neoplasias Gástricas/epidemiologia , Redução de PesoRESUMO
Melatonin has been shown to exert anticancer activity on hepatocellular carcinoma (HCC) through its antiproliferative and pro-apoptotic effect in both experimental and clinical studies, and sorafenib is the only approved drug for the systemic treatment of HCC. Thus, this study was designed to investigate the combined effect of melatonin and sorafenib on proliferation, apoptosis, and its possible mechanism in human HCC. Here, we found that both melatonin and sorafenib resulted in a dose-dependent growth inhibition of HuH-7 cells after 48 hours treatment, and the combination of them enhanced the growth inhibition in a synergistic manner. Colony formation assay indicated that co-treatment of HuH-7 cells with melatonin and sorafenib significantly decreased the clonogenicity compared to the treatment with single agent. Furthermore, FACS and TUNEL assay confirmed that melatonin synergistically augmented the sorafenib-induced apoptosis after 48 hours incubation, which was in accordance with the activation of caspase-3 and the JNK/c-jun pathway. Inhibition of JNK/c-jun pathway with its inhibitor SP600125 reversed the phosphorylation of c-jun and the activation of caspase-3 induced by co-treatment of HuH-7 cells with melatonin and sorafenib in a dose-dependent manner. Furthermore, SP600125 exhibited protective effect against apoptosis induced by the combination of melatonin and sorafenib. This study demonstrates that melatonin in combination with sorafenib synergistically inhibits proliferation and induces apoptosis in human HCC cells; therefore, supplementation of sorafenib with melatonin may serve as a potential therapeutic choice for advanced HCC.
Assuntos
Carcinoma Hepatocelular , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Neoplasias Hepáticas , MAP Quinase Quinase 4/metabolismo , Melatonina/farmacologia , Proteínas de Neoplasias/metabolismo , Niacinamida/análogos & derivados , Compostos de Fenilureia/farmacologia , Transdução de Sinais/efeitos dos fármacos , Antracenos/farmacologia , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patologia , Caspase 3/metabolismo , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patologia , Niacinamida/farmacologia , SorafenibeRESUMO
Hepatocellular carcinoma (HCC) is a highly vascularized tumor with limited susceptibility to chemotherapy. Modern targeted therapies are aimed at specific properties of this neoplasm. Glycine is a simple non-essential amino acid with potential antiangiogenic effects. In this study, the amino acid's effect on angiogenic signaling in an in vitro model of HCC was evaluated. HepG2 and Huh7 cells were treated with glycine-free DMEM supplemented with 0, 0.01, 0.1, 1.0, 2.0, 5.0 and 10 mM glycine. The direct effects of glycine on the viability of HCC cells were monitored using MTT assay. To detect angiogenic signaling, mRNA and protein levels of vascular endothelial growth factor (VEGF-A) were measured using RT-PCR and Western Blot assays. To determine whether or not glycine receptors (GlyR) played a significant role, the specific antagonist, strychnine, was used as a direct inhibitor. Western Blotting was performed to show the presence of GlyR. While there was no direct pro- or antiproliferative effect of either glycine or strychnine in both cell lines, glycine was shown to significantly decrease VEGF-A expression on mRNA and protein level up to 63 % in both cell lines. This effect was blunted by the presence of strychnine. GlyR was also identified in both cell lines. Glycine decreases GlyR-dependent, VEGF-A-mediated, angiogenic signaling in human HCC and thus might be a promising additive to chemotherapy treatment strategies for highly vascularized tumors.